Clinical significance of brachial flow-mediated dilation in patients with rheumatoid arthritis
Article first published online: 18 JAN 2013
© 2013 The Authors International Journal of Rheumatic Diseases © 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
International Journal of Rheumatic Diseases
Volume 17, Issue 1, pages 26–33, January 2014
How to Cite
Watanabe, T., Takemura, M., Sato, M., Matsunami, H., Seishima, M., Shimizu, K. and Matsuoka, T. (2014), Clinical significance of brachial flow-mediated dilation in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases, 17: 26–33. doi: 10.1111/1756-185x.12021
- Issue published online: 28 JAN 2014
- Article first published online: 18 JAN 2013
- brachial flow-mediated dilation;
- carotid intima-media thickness;
- rheumatoid arthritis;
This study aimed to clarify whether different anti-tumor necrosis factor (TNF) drugs can improve endothelial function better than conventional disease-modifying anti-rheumatic drugs (DMARDs) in a series of Japanese patients with rheumatoid arthritis (RA).
Twenty-five patients who met the American College of Rheumatology 1987 revised diagnostic criteria for RA were randomly selected for this study. The percentage of brachial flow-mediated dilation (%FMD) and maximum carotid intima-media thickness were examined by ultrasonography.
The %FMD in the group treated with anti-TNF therapy was significantly higher than that in the group treated with DMARDs (P < 0.001). The %FMD was significantly correlated with anti-TNF therapy (r = 0.684, P < 0.001) and Disease Activity Score C-reactive protein (r = –0.404, P < 0.05). Multiple regression analysis revealed that anti-TNF therapy was significantly associated with %FMD (β = 0.684, P < 0.001).
Anti-TNF therapy may influence endothelial function more than conventional DMARD therapy. Prospective longitudinal studies examining whether anti-TNF therapy was able to improve endothelial function are required.